All Outputs (27)

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease (2023)
Journal Article
Munir, T., Cairns, D. A., Bloor, A., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Walewska, R., Duley, L., Howard, D., …Hillmen, P. (2024). Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease. New England Journal of Medicine, 390(4), 326-337. https://doi.org/10.1056/NEJMoa2310063

BACKGROUND: The combination of ibrutinib and venetoclax has been shown to improve outcomes in patients with chronic lymphocytic leukemia (CLL) as compared with chemoimmunotherapy. Whether ibrutinib-venetoclax and personalization of treatment duration... Read More about Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.

Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis (2023)
Journal Article
Mohamed, E., García Martínez, D. J., Hosseini, M. S., Yoong, S. Q., Fletcher, D., Hart, S., & Guinn, B. A. (2024). Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis. Carcinogenesis, 45(1-2), Article bgad091. https://doi.org/10.1093/carcin/bgad091

Lung cancer (LC) causes few symptoms in the earliest stages, leading to one of the highest mortality rates among cancers. Low-dose computerised tomography (LDCT) is used to screen high-risk individuals, reducing the mortality rate by 20%. However, LD... Read More about Identification of biomarkers for the early detection of non-small cell lung cancer: a systematic review and meta-analysis.

Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis (2023)
Journal Article
Batten, L., Sathyapalan, T., & Palmer, T. M. (2023). Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis. International Journal of Molecular Sciences, 24(24), Article 17465. https://doi.org/10.3390/ijms242417465

This review will provide an overview of what is currently known about mechanisms linking poor glycaemic control with increased thrombotic risk. The leading causes of death in people with diabetes are strokes and cardiovascular disease. Significant mo... Read More about Molecular Mechanisms Linking Diabetes with Increased Risk of Thrombosis.

Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials (2023)
Journal Article
Molica, S., & Allsup, D. (2023). Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials. Expert Review of Anticancer Therapy, https://doi.org/10.1080/14737140.2023.2288899

Introduction: Chronic lymphocytic leukemia (CLL) management has witnessed a transformative shift with the advent of time-limited venetoclax and anti-CD20 monoclonal antibody (mAb) regimens, as exemplified by the groundbreaking MURANO and CLL14 trials... Read More about Fixed-duration therapy comes of age in CLL: long-term results of MURANO and CLL14 trials.

Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (in press). Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions. Hematological Oncology, https://doi.org/10.1002/hon.3238

In the modern era of Chronic Lymphocytic Leukemia (CLL) targeted therapy, the loss of p53 function due to genetic abnormalities remains a significant challenge. This is because even targeted agents, which are currently the mainstay of treatment for C... Read More about Targeting TP53 disruption in chronic lymphocytic leukemia: Current strategies and future directions.

The role of WSB-1 as a BRCAness biomarker in breast cancer (2023)
Thesis
Li, . C. (2023). The role of WSB-1 as a BRCAness biomarker in breast cancer. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4436228

Background Radiotherapy currently has become one of the major therapeutic approaches in the treatments for cancers. However, hypoxia presents a significant challenge to the effectiveness of radiotherapy and is associated with radio-resistance. Previ... Read More about The role of WSB-1 as a BRCAness biomarker in breast cancer.

Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study (2023)
Presentation / Conference Contribution
Hillmen, P., Cairns, D. A., Bloor, A. J. C., Allsup, D., Cwynarski, K., Pettitt, A., Paneesha, S., Fox, C. P., Eyre, T. A., Forconi, F., Elmusharaf, N., Kennedy, B., Gribben, J. G., Pemberton, N., Sheehy, O., Preston, G., Schuh, A., Howard, D., Hockaday, A., Jackson, S., …Munir, T. Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA

Introduction: Ibrutinib (I), an irreversible Btk inhibitor, and venetoclax (V), a Bcl-2 inhibitor, improve CLL outcomes in trials compared to chemoimmunotherapy. I and V target two key pathophysiological pathways in CLL and should be synergistic. Thi... Read More about Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study.

Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial (2023)
Presentation / Conference Contribution
Rawstron, A., Webster, N., Dalal, S., de Tute, R. M., Bell, S., Cairns, D. A., Girvan, S., Greatorex, N., Hockaday, A., Jackson, S., Phillips, D., Stones, D., Allsup, D., Bloor, A. J. C., Sarma, A., Varghese, A. M., Munir, T., & Hillmen, P. Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. Presented at 65th ASH Annual Meeting and Exposition, San Diego, CA

Identification of Novel Glucose-Dependent Alterations Responsible for Vascular Dysfunction in Type 2 Diabetes Mellitus (T2DM) I (2023)
Thesis
Bolanle, O. I. (2023). Identification of Novel Glucose-Dependent Alterations Responsible for Vascular Dysfunction in Type 2 Diabetes Mellitus (T2DM) I. (Thesis). Hull York Medical School. https://hull-repository.worktribe.com/output/4420724

Despite the plethora of drugs currently available for managing coronary artery disease (CAD) patients with or without type 2 diabetes mellitus (T2DM), yet CAD frequently progresses, necessitating a coronary artery bypass graft (CABG) procedure using... Read More about Identification of Novel Glucose-Dependent Alterations Responsible for Vascular Dysfunction in Type 2 Diabetes Mellitus (T2DM) I.

Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress (2023)
Journal Article
Connolly, D., Madden, L. A., Edwards, V., D'Oyly, T., Harridge, S., Smith, T., & Lee, V. (2023). Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress. Aerospace Medicine and Human Performance, 94(10), 738-749. https://doi.org/10.3357/AMHP.6247.2023

INTRODUCTION: Consistent blood biomarkers of hypobaric (altitude) decompression stress remain elusive. Recent laboratory investigation of decompression sickness risk at 25,000 ft (7620 m) enabled evaluation of early pathophysiological responses to ex... Read More about Early Human Pathophysiological Responses to Exertional Hypobaric Decompression Stress.

In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models (2023)
Journal Article
Moris, N., & Sturmey, R. (2023). In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models. Development, 150(17), Article dev202295. https://doi.org/10.1242/dev.202295

Several exciting advances have enabled the derivation of stem cell-based embryo-like models (SCBEMs). Such models allow us to interrogate previously intractable questions in developmental biology and ask hypothesis-driven fundamental questions such a... Read More about In preprints: opportunities to unravel the earliest stages of human development using stem cell-based embryo models.

Investigating protein arginine methylation in platelets and hair (2023)
Thesis
Marsden, A. J. (2023). Investigating protein arginine methylation in platelets and hair. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4386508

Post-translational modification (PTM) of platelet proteins has long been known to have an effect on their ability to aggregate and form a thrombus. Arginine methylation (ArgMe) is catalysed by protein arginine methyltransferases (PRMTs) which... Read More about Investigating protein arginine methylation in platelets and hair.

Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide (2023)
Journal Article
Molica, S., Rossi, M., & Allsup, D. (2023). Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide. Acta Haematologica, 147(3), 257-259. https://doi.org/10.1159/000533349

In addition to the European Society for Medical Oncology (ESMO) and National Comprehensive Cancer Network (NCCN) guidelines that are reference standards for the treatment of chronic lymphocytic leukemia (CLL) in Europe and the USA, several consensus... Read More about Consensus Statements Highlight the Need of Harmonizing Chronic Lymphocytic Leukemia Management Worldwide.

Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option (2023)
Journal Article
Molica, S., Tam, C., Allsup, D., & Polliack, A. (2023). Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option. Cancers, 15(14), Article 3737. https://doi.org/10.3390/cancers15143737

Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, howev... Read More about Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option.

A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis (2023)
Journal Article
Morris, V., Ghazi, H., Fletcher, D., & Guinn, B. A. (2023). A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 24(11), Article 9667. https://doi.org/10.3390/ijms24119667

Acute myeloid leukaemia (AML) is characterized by impaired myeloid differentiation resulting in an accumulation of immature blasts in the bone marrow and peripheral blood. Although AML can occur at any age, the incidence peaks at age 65. The pathobio... Read More about A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.

Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer. (2023)
Presentation / Conference Contribution
Nikitenko, L. L., Manolis, D., O'Brien, D. P., Adekeye, A., Kessler, B. M., Collins, C., Kramer, H., Chang, D., & Maraveyas, A. Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer. Presented at The London Pancreas Workshop 2023, London, United Kingdom

In our EARLY DIAgnosis of PAncreatic Cancer (EARLY DIAPAC) study, we aim to analyse molecular changes or “signatures” associated with early stages of pancreatic carcinogenesis by using the combination of: (i) Label-Free Quantitative Proteomics (LFQP)... Read More about Quantitative proteomics of pancreatic cyst fluid for early diagnosis of cancer..

A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells (2023)
Journal Article
Guinn, B. A., Schuler, P. J., Schrezenmeier, H., Hofmann, S., Weiss, J., Bulach, C., …Greiner, J. (2023). A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells. International Journal of Molecular Sciences, 24(11), Article 9285. https://doi.org/10.3390/ijms24119285

Immune checkpoint inhibitors can block inhibitory molecules on the surface of T cells, switching them from an exhausted to an active state. One of these inhibitory immune checkpoints, programmed cell death protein 1 (PD-1) is expressed on T cell subp... Read More about A Combination of the Immunotherapeutic Drug Anti-Programmed Death 1 with Lenalidomide Enhances Specific T Cell Immune Responses against Acute Myeloid Leukemia Cells.

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial (2023)
Journal Article
Hillmen, P., Pitchford, A., Bloor, A., Broom, A., Young, M., Kennedy, B., Walewska, R., Furtado, M., Preston, G., Neilson, J. R., Pemberton, N., Sidra, G., Morley, N., Cwynarski, K., Schuh, A., Forconi, F., Elmusharaf, N., Paneesha, S., Fox, C. P., Howard, D. R., …Munir, T. (2023). Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. The lancet oncology, 24(5), 535-552. https://doi.org/10.1016/S1470-2045%2823%2900144-4

Background: The approval of Bruton tyrosine kinase (BTK) inhibitors in patients with previously untreated chronic lymphocytic leukaemia (CLL) was based on trials which compared ibrutinib with alkylating agents in patients considered unfit for fludara... Read More about Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial.

The Host-Microbiota Axis in Chronic Wound Healing (2023)
Thesis
Stafford, A. R. (2023). The Host-Microbiota Axis in Chronic Wound Healing. (Thesis). Hull York Medical School. https://hull-repository.worktribe.com/output/4424929

Chronic, non-healing skin wounds represent a substantial area of unmet clinical need, leading to debilitating morbidity and mortality in affected individuals. Due to their high prevalence and recurrence, chronic wounds pose a significant economic bur... Read More about The Host-Microbiota Axis in Chronic Wound Healing.

Factor VII deficiency: a cause of (or risk factor for) bleeding? (2023)
Journal Article
Hampshire, D. J. (2023). Factor VII deficiency: a cause of (or risk factor for) bleeding?. British journal of haematology, 202(3), 457-458. https://doi.org/10.1111/bjh.18806

Among the rare bleeding disorders factor VII deficiency is the most common, but correlating deficiency with bleeding phenotype is challenging. In their study Lou and colleagues investigate a large cohort of unrelated factor VII deficient patients pro... Read More about Factor VII deficiency: a cause of (or risk factor for) bleeding?.